112 results about "Migraine" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a preparation method of a CGRP detection kit and application of the CGRP detection kit in migraine diagnosis, and belongs to the technical field of biological medicine detection. According to the invention, alpha-CGRP polypeptide coupled KLH protein is subjected to efficient animal immunization, an antibody with good affinity is screened by using methods such as enzyme-linked immunosorbent assay, cross pairing analysis is carried out, and final antibody sequence information is obtained through sequencing. The paired monoclonal antibody screened by the invention has high sensitivity (KD value of 1nM), the limit of detection (LoD) can be as low as pg / mL level, a low-concentration CGRP sample can be effectively detected, the matrix effect of human serum / plasma can be effectively neutralized by an optimized sample diluent formula, and the repeatability is high (in-plate and inter-plate CV values of 1t and 10%). According to the invention, the kit prepared from the specific paired antibody is systematically and closely linked with the indication function of migraine for the first time, and a clinical diagnosis direction is provided.

The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.

A migraine pain mitigation device includes a headband which fits around the head of a user and at least one pressure-applying ball supported by the headband for applying pressure to a point on the head of the user. The tightness of the headband on the head of the user is adjustable. The position of each pressure-applying ball can be adjusted in the circumferential direction of the headband without the user having to remove the headband from the user's head.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Methods for using gene expression changes and mutations in neural organoids to identify and assess effectiveness of treatment methodologies and effective pharmaceutical compositions for treating chronic and neuropathic pain including headache and migraines are disclosed.

A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

The application provides a multifunctional therapeutic instrument for migraine relief, which comprises a treatment frame, a slidingly installed mounting seat arranged on the treatment frame, a first hot compress pad arranged on the mounting seat, a fixed shell arranged on the treatment frame, a connecting hole arranged on the fixed shell, a movable frame arranged in the fixed shell, a connecting shaft arranged on the movable frame, the connecting shaft being rotatably arranged in the connecting hole, a sliding frame arranged in the movable frame, a mounting rod slidably arranged in the sliding frame, a pressing plate hingedly arranged at one end of the mounting rod, and a second hot compress pad arranged on the bottom surface of the pressing plate. The therapeutic instrument can effectively relax the tense muscles and nerves of the head and neck through the form of hot compress on the back of the neck and the forehead, so as to achieve the effect of relieving migraine, and the position of the hot compress pad can be conveniently adjusted for different people, and the hot compress pad is not easy to be separated.

The invention relates to an application of a halophenol compound 2, 4 ', 5'-trihydroxy-5, 2 '-dibromo benzophenone in preparation of an analgesic drug. Experiments prove that the compound has a definite analgesic effect, can significantly inhibit mouse writhing reaction induced by acetic acid and II-phase inflammatory pain induced by formalin, and prolongs the thermal stimulation tail retraction incubation period, and the effect is superior to that of aspirin. Furthermore, in a nitroglycerin-induced migraine rat model, the compound can effectively improve behavioral symptoms and brain tissue pathological damage and remarkably regulate key index levels of CGRP, PGE2, ET-1, IL-1beta, IL-6, TNF-alpha, 5-HT and the like in plasma, which shows that the compound can be applied to preparation of analgesic drugs, preparation of drugs for treating migraine, preparation of drugs for treating migraine and the like. The invention particularly has important application value in medicines for preventing and / or treating migraine.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. The compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. The use of compound C having formula (I'), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the preparation of pharmaceutical compositions for the treatment or prevention of disorders for which ASIC inhibitors are indicated is also provided. In some embodiments, pharmaceutical compositions prepared using the compound of formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or compound C, are for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511139000245.jpg21170

The present invention relates to a pharmaceutical composition. The pharmaceutical composition comprises cobra cardiotoxin (CDX) and a pharmaceutically acceptable carrier thereof. The pharmaceutical composition is further characterized by comprising use of cobra cardiotoxin (CDX) in combination with any one or both of the following drugs for treating migraine: cobra phospholipase A2 (PLA2) and cobra neurotoxin (NTX). The pharmaceutical composition can be used for preventing and treating migraine and down-regulating the concentration of nitric oxide (NO) in migraine patients. The pharmaceutical composition is of great significance for the treatment of migraine.

This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.

The present disclosure relates to a method for providing information for diagnosing migraine and, more specifically, to a method for accurately and quickly diagnosing migraine without pain or discomfort to a patient, the method comprising a step of measuring the relative abundance of at least one bacterium selected from the group consisting of Gemella haemolysans, Centipeda periodontii, Cardiobacterium valvarum, Catonella morbi, and Selenomonas noxia in a biological sample.

A pharmaceutical composition for intranasal administration and manufacturing method of preparations containing a combination of ibuprofen and ketoprofen at a fraction of the dose required when the same active ingredients are administered orally, useful in the treatment of migraine and other forms of headache.

The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing same, and a use of same for treating diseases and disorders affected by neuronal damage, for example: cerebral stroke, brain damage, neuropathic pain, migraines, inflammatory pain, chronic pain, or depression. The definition of each group in the general formula (I) is the same as that in the description.

The invention belongs to the field of marker detection, and particularly relates to a marker for diagnosing or identifying potential causes of migraine, application, a kit, a device and an evaluation model. The invention provides a marker for diagnosing or identifying potential causes of migraine. The marker comprises indoleacrylic acid and / or hypersensitive C-reactive protein. The invention reveals that PFO is combined with migraine metabonomics maps, and branched chain amino acid metabolism, neurosteroid metabolism and tryptophan metabolism disorder are core pathological mechanisms for the first time. On the basis of plasma metabonomics characteristics of a PFO-combined migraine patient and a healthy control, 211 metabolites with significant difference are screened out, it is found that various metabolites are significantly related to the symptom severity of migraine, and two factors [indoleacrylic acid and hypersensitive C-reactive protein (hs-CRP)] significantly related to migraine related to patent foramen ovale are confirmed. In addition, the concentration of indolecrylic acid (IA) is found to have a relatively good prediction value on symptom relief after occlusion.

This document provides methods and processes involved in receiving one or more inputs from a subject having a disease or disorder associated with head pain, wherein the one or more inputs are received over a predetermined amount of time, extracting one or more features from the one or more inputs, analyzing the one or more features by determining at least the slope, intercept, and frequency of the one or more features, recommending a treatment plan for the subject based on the analysis of the one or one or more features, and providing one or more treatments to the subject based on the recommendation are provided.

A multi-purpose medicinal cream comprising shea butter, wild opium lettus powder, Orange Blood, Frankincense, Lavender, Rosemary, Copaiba Balsam, Birch Sweet, Lemon Grass, Marjoram, Basil, Eucalyptus, Peppermint, Cinnamon, Cedarwood, Thyme, Clove, Vetiver, Geranium, Cinnamon Leaf, and Ylang Ylang. The multi-purpose cream is an aid in pain management of disorders including lupus, arthritis, rheumatoid arthritis, knee and joint pain, neck pain, inflammation, migraines, and neuropathic disorders, as well the treatment of skin conditions including eczema, dry skin, psoriasis, swelling, heat rash, rashes, and rashes of dogs.

The invention provides a foramen ovale migraine target-oriented electroencephalogram signal analysis method and system, and relates to the technical field of signal processing.The method comprises the steps that spatial registration is conducted on electrode coordinates and brain structure images, and a mapping relation is established; obtaining an initial coordinate of an oval foramen migraine associated target brain region, screening a target associated electrode according to the mapping relation, and finely adjusting the initial coordinate; configuring electroencephalogram acquisition equipment parameters, and acquiring original electroencephalogram signals; and performing preprocessing and feature extraction, performing analysis processing on the target feature set through a pre-trained feature quantitative analysis model, and outputting a feature similarity score and a visual analysis report of the target electroencephalogram signal. The technical problems that in the prior art, due to the fact that the signal collection range is wide, noise interference of an irrelevant area is serious, effective signals of a target area are submerged, and the signal analysis precision is further affected are solved, accurate processing of the electroencephalogram signals of the foramen ovale migraine associated target is achieved, and the signal analysis precision is improved.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of medical equipment, in particular to an ear mold 3D printing and electrical stimulation integrated treatment system for migraine, and the system comprises an auricle data collection module which collects the three-dimensional geometric data, auricular point positioning data and skin impedance distribution data of the auricle of a patient; the personalized ear mold generation module constructs a personalized ear mold with a built-in bionic radian electrode channel through a self-adaptive layered 3D printing algorithm, and alignment of the electrode channel and a target auricular point is carried out; the intelligent electrical stimulation regulation and control module is combined with an improved targeted Attention-LSTM model to dynamically adjust the electrical stimulation frequency, the pulse width and the stimulation intensity so as to generate a personalized electrical stimulation scheme; and the execution and safety monitoring module converts the personalized electrical stimulation scheme into a targeted electrical stimulation physical treatment process, and performs dynamic monitoring and adaptive adjustment in the whole treatment process. Therefore, the problems of single auricle data acquisition dimension, obvious personalized ear mold printing and adaptability defects and the like in the prior art are solved.

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

The invention relates to aqueous, oral formulations of diclofenac that provide both rapid and sustained relief from acute pain. The invention further relates to pharmaceutical compositions comprising the compounds, methods of making the aqueous pharmaceutical compositions and methods of using the compounds treating pain, including, but not limited to migraines.

A sterol-based compound of formula (I) for its use in preventing, ameliorating and / or treating a mitochondrial deficiency-related pathology chosen from the group consisting of autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related mental pathologies, ataxia, neuropathies, smoking-related cerebral and pulmonary disorders, MERRF syndrome and NARP syndrome. A pharmaceutical composition comprising at least one compound of formula (I).

The present invention is related to methods of treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, with a therapeutically effective amount of a compound having a structure according to the formula:the method comprising nasally administering to the patient (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg / mL±50 mg / mL, and wherein the second dose of the compound is administered between 5 minutes and 25 minutes after the first dose.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.